WebApr 18, 2024 · At ASCO GU 2024, I presented this initial analysis of cohort H from the ongoing phase I/II EV-103 study evaluating neoadjuvant enfortumab vedotin followed by surgery. 14 The 22 patients in this cohort had muscle-invasive disease and were cisplatin ineligible at enrollment. Enfortumab vedotin was given at a dose of 1.25 mg/kg on Day 1 … WebFeb 16, 2024 · Pts with pT1 disease are eligible only if they have N1 disease. Pts receive 3 cycles of neoadjuvant EV (1.25 mg/kg IV) on Days 1 and 8 of each 3-week cycle, followed by RC+PLND and then 6 cycles of adjuvant EV starting 8 weeks post-RC on the same schedule. Pathological complete response rate per central pathology review is the …
Study EV-103: Update on durability results and long ... - ASCO Publicati…
WebApr 11, 2024 · Efficacy was evaluated in EV-103/KEYNOTE-869 (NCT03288545), a multi-cohort (dose escalation cohort, Cohort A, Cohort K) study. The dose escalation cohort and Cohort A were single-arm cohorts treating patients with enfortumab vedotin-ejfv plus pembrolizumab while patients on Cohort K were randomised to either the combination or … WebFeb 14, 2024 · Cohort H of the phase 1b /2 EV-103 trial enrolled patients with MIBC who were eligible for surgical treatment but ineligible for cisplatin-based chemotherapy. … birmingham airport hotel and parking packages
Seagen - Seagen to Highlight Research in Urothelial and …
WebApr 14, 2024 · Design, Setting, and Participants This economic evaluation used simulation modeling and cost-effectiveness with costs and quality-adjusted life-years (QALYs) discounted at 3% to compare MOUD treatment strategies in a corrections cohort and an open cohort representing individuals with OUD in Massachusetts. Data were analyzed … WebASCO GU 2024 on EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment With Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible MIBC. By ASCO Genitourinary Cancers Symposium FEATURING Nataliya Mar. March 23, 2024 0 Comments . Login to view comments. Click here to Login. Featured Video. 19:41 ... WebSep 12, 2024 · Cohort K of the EV-103/KEYNOTE-869 trial is a randomized 1:1 cohort investigating enfortumab vedotin alone (n=73) or in combination with pembrolizumab (n=76) in adult patients with unresectable la/mUC who are ineligible for cisplatin-based chemotherapy and have received no prior treatment for la/mUC. The enfortumab vedotin … birmingham airport flights 2023